ArticleJournal of neurology2026
Blood biomarkers of brain damage in Transient Ischemic Attack: the role of plasma NfL and GFAP.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTransient Ischemic Attack (TIA) may induce subtle tissue damage that remains undetectable on conventional magnetic resonance imaging (MRI), which has led to growing interest in blood biomarkers of neuronal and glial injury. This study examined whether plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) can distinguish patients with clinically defined, MRI-negative TIA from healthy individuals.
methodsSingle-center retrospective study that included clinical TIA patients with negative MRI. Age- and sex-matched healthy controls were selected. A blood sample was collected within 24 h from admission, and plasma NfL and GFAP were measured using Simoa technology. We performed group comparisons, ROC analyses with identification of optimal thresholds, and evaluation of combined diagnostic assessment. Sensitivity analyses excluding patients with pre-existing disability, previous stroke/TIA, impaired renal function, high MRI small vessel disease burden and moderate-severe cerebral cortical atrophy were performed.
results36 TIA patients and 72 controls were analyzed. TIA patients showed higher NfL (27.22 vs 10.44 pg/mL, p<0.001) and GFAP (301.99 vs 131.65 pg/mL, p<0.001) levels. Optimal thresholds were 16.83 pg/mL for NfL (sensitivity 52.8%, specificity 98.6%) and 179.23 pg/mL for GFAP (sensitivity 69.4%, specificity 81.9%). Combined assessment increased sensitivity to 80.6% while maintaining specificity at 81.9% with the highest discriminative accuracy (AUC 0.812). The significantly higher level of NfL and GFAP in TIA patients was confirmed in sensitivity analyses. DISCUSSION: NfL and GFAP are elevated in MRI-negative TIA, supporting the presence of transient microscopic brain injury. Larger studies are needed to confirm clinical utility.
Indexed as
Identifiers
42711449What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.